[{"orgOrder":0,"company":"Lifeward","sponsor":"Oramed Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"ISRAEL","productType":"Hormone","year":"2026","type":"Partnership","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Lifeward","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0.050000000000000003,"dosageForm":"Capsule","sponsorNew":"Lifeward \/ Oramed Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Lifeward \/ Oramed Pharmaceuticals"}]

Find Clinical Drug Pipeline Developments & Deals by Lifeward

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          VMX
                          Not Confirmed
                          VMX
                          Not Confirmed

                          Details : As part of the partnership, Insulin will be developed to target the Insulin receptor for type 2 diabetes treatment.

                          Product Name : ORMD-0801

                          Product Type : Hormone

                          Upfront Cash : Undisclosed

                          January 13, 2026

                          Lead Product(s) : Insulin

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase III

                          Sponsor : Oramed Pharmaceuticals

                          Deal Size : $47.0 million

                          Deal Type : Partnership

                          blank